Phytochemical regulation of the tumor suppressive microRNA, miR-34a, by p53-dependent and independent responses in human breast cancer cells

Molecular Carcinogenesis

Volumn 55, Issue 5, 2016, Pages 486-498

  Hargraves, Kris G ^a   He, Lin ^a   Firestone, Gary L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Anti proliferative response; Artemisinin; Artesunate; CDK4; Indole 3 carbinol

Indexed keywords

3 INDOLEMETHANOL; ARTEMISININ; ARTESUNATE; CYCLIN DEPENDENT KINASE 4; LUCIFERASE; MICRORNA 34A; PROTEIN P53; ANTINEOPLASTIC AGENT; ARTEMISININ DERIVATIVE; CDK4 PROTEIN, HUMAN; INDOLE DERIVATIVE; INDOLE-3-CARBINOL; MICRORNA; MIRN34 MICRORNA, HUMAN; TP53 PROTEIN, HUMAN;

3' UNTRANSLATED REGION; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BINDING SITE; BREAST CANCER; CELL CYCLE ARREST; CONTROLLED STUDY; CORRELATIONAL STUDY; DOWN REGULATION; ENZYME ACTIVITY; FLOW CYTOMETRY; GENE TARGETING; HUMAN; HUMAN CELL; MCF 7 CELL LINE; PRIORITY JOURNAL; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; RNA EXTRACTION; UPREGULATION; WESTERN BLOTTING; WILD TYPE; BREAST TUMOR; CELL PROLIFERATION; DOSE RESPONSE; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; GENETICS; MCF-7 CELL LINE; METABOLISM; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; ARTEMISININS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE 4; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INDOLES; MCF-7 CELLS; MICRORNAS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84925249775     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.22296     Document Type: Article

References (55)

1. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009; 136: 215-233.
2. Filipowicz W, Bhattacharyya SN, Sonenberg N. Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight. Nat.Rev. Genet. 2008; 9: 102-114.
3. Lim LP, Lau NC, Garrett-Engele P, et al. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature 2005; 433: 769-773.
4. Ambros V. The functions of animal microRNAs. Nature 2004; 431: 350-355.
5. Friedman RC, Farth KK, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 2009; 19: 92-105.
6. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005; 120: 15-20.
7. Lujambio A, Lowe SW. The microcosmos of cancer. Nature 2012; 482: 347-355.
8. He L, He X, Lowe SW, Hannon GJ. MicroRNAs join the p53 network-another piece in the tumor-suppression puzzle. Nat Rev Cancer 2007; 7: 819-822.
9. Croce CM, Calin GA. MicroRNA-cancer connection: the beginning of a new tale. Cancer Res 2006; 66: 7390-7394.
10. Olivier M, Hollsetin M, Hainaut P. Tp53 mutations in human cancers: origins, consequences and clinical use. Cold Spring Harb Perspect Biol 2010; 2: a001008.
11. Juntilla M, Evan G. P53-a Jack of all trades but master of none. Nat Rev Cancer 2009; 9: 821-829.
12. Hermeking H. The miR-34 family in cancer and apoptosis. Cell Death Differ 2009; 17: 193-199.
13. Wong MYW, Yu Y, Walsh WR, Yang JL. MicroRNA-34 family and treatment of cancers with mutant or wild-type p53. Int J Oncol 2011; 38: 1189-1195.
14. He L, He X, Lim LP, et al. A microRNA component of the p53 tumor suppressor network. Nature 2007; 447: 1130-1134.
15. Vogt M, Munding J, Grüner M, et al. Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas. Virchows Arch 2011; 458: 313-322.
16. Lodygin D, Tarasov V, Epanchintsev A, et al. Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. Cell Cycle 2008; 7: 2591-2600.
17. Yang S, Li Y, Gao J, et al. MicroRNA-34 suppressesbreast cancerinvasion and metastasis by directly targeting Fra-1. Oncogene 2013;:324294-324303.
18. Peurala H, Greco D, Heikkinen T, et al. MiR-34a expression has an effect for lower risk of metastasis and associates with expression patterns predicting clinical outcome in breast cancer. PLoS ONE 2011; 6: e26122.
19. Mackiewicz M, Huppi K, Pitt JJ, et al. Identification of the receptor tyrosine kinase Axl in breast cancer as a target for the human miR-34a microRNA. Breast Cancer Res Treat 2011; 130: 663-679.
20. Li X, Ji M, Zhong S, et al. MicroRNA-34a modulates chemosensitivity ofbreast cancercells to adriamycin by targeting Notch1. Arch Med Res 2012; 43: 514-521.
21. Li L, Yuan L, Luo J, Gao J, Guo J, Xie X. MiR-34a inhibits proliferation and migration of breast cancer through down-regulation of Bcl-2 and SIRT1. Clin Exp Med 2013; 13: 109-117.
22. Firestone GL, Sundar SN. Minireview: modulation of hormone receptor signaling by dietary anticancer indoles. Mol Endocrinol 2009; 23: 1940-1947.
23. Weng JR, Tsai CH, Kulp S, Chen CS. Indole-3-carbinol as a chemopreventive and anti-cancer agent. Cancer Lett 2008; 262: 153-163.
24. Firestone GL, Sundar SN. Anticancer activities of artemisinin and its bioactive derivatives. Expert Rev Mol Med 2009; 11: 1-15.
25. Liu WM, Gravatt AM, Dalgleish AG. The antimalarial agent artesunate possess anticancer properties that can be enhanced by combination strategies. Int J Cancer 2011; 128: 1471-1480.
26. Efferth T. Willmar Schwabe Award 2006: antiplasmodial and antitumor activity of artemisinin-from bench to bedside. Planta Med 2007; 73: 299-309.
27. Brew CT, Aronchik I, Hsu JC, et al. Indole-3-carbinol activates the ATM signaling pathway independent of DNA damage to stabilize p53 and induce G1 arrest of human mammary epithelial cells. Int J Cancer 2006; 118: 857-868.
28. Tin AS, Sundar SM, Tran KQ, Park AH, Poindexter KM, Firestone GL. Anti-proliferative effects of artemisinin on human breast cancer cells requires the downregulated expression of the E2F1 transcription factor and loss of E2F1-target cell cycle genes. Anticancer Drugs 2012; 4: 370-379.
29. Willoughby JA, Sundar SN, Cheung M, Tin AS, Modiano J, Firestone GL. Artemisinin blocks prostate cancer growth and cell cycle progression by disrupting Sp1 interactions with the cyclin-dependent kinase-4 (CDK4) promoter and inhibiting CDK4 gene expression. J Biol Chem 2009; 284: 2203-2213.
30. Zhang HT, Wang YL, Zhang J, Zhang QX. Artemisinin inhibits gastric cancer cell proliferation through upregulation of p53. Tumour Biol 2014; 35: 1403-1409.
31. Sertel S, Eichhorn T, Simon CH, Plinkert PK, Johnson SW, Efferth T. Pharmacogenomic identification of c-Myc/Max-regulated genes associated with cytotoxicity of artesunate towards human colon, ovarian and lung cancer cell lines. Molecules 2010; 15: 2886-2910.
32. Efferth T, Oesch F. Oxidative stress response of tumor cells: microarray-based comparison between artemisinins and anthracyclines. Biochem Pharmacol 2004; 68: 3-10.
33. Neve RM, Chin K, Fridlyand J, et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006; 10: 515-527.
34. Staub RE, Feng C, Onisko B, Bailey GS, Firestone GL, Bjeldanes LF. Fate of indole-3-carbinol in cultured human breast tumor cells. Chem Res Toxicol. 2002; 15: 101-109.
35. Voljtěšek B, Lane DP. Regulation of p53 protein expression in human breast cancer cell lines. J Cell Sci 1993; 105: 607-612.
36. Lukashchuk N, Vousden KH. Ubiquitination and degradation of mutant p53. Mol Cell Biol 2007; 27: 8284-8295.
37. Haynes R, Chan HW, Lung CM, Ng NC, Wong HN, Shek LY. Artesunate and dihydroartemisinin (DHA): unusual decomposition products formed under mild conditions and comments on the fitness of DHA as an anti-malarial drug. Chem Med Chem 2007; 2: 1448-1463.
38. Li Y, Kong D, Wang Z, Sarkar FH. Regulation of microRNAs by natural agents: an emerging field in chemoprevention and chemotherapy research. Pharm Res 2010; 6: 1027-1041.
39. Sarkar FH, Li Y, Wang Z, Kong D, Ali S. Implication of microRNAs in drug resistance for designing novel cancer therapy. Drug Resist Update 2010; 13: 57-66.
40. Paik WH, Kim HR, Park JK, Song BJ, Lee SH, Hwang JH. Chemosensitivity induced by down-regulation of microRNA-21 in gemcitabine-resistant pancreatic cancer cells by indole-3-carbinol. Anticancer Res 2013; 3: 1473-1481.
41. Izzotti A, Calin GA, Steele VE, Cartiglia C, Longobardi M, Croce CM. Chemoprevention of cigarette smoke-induced alterations of MicroRNA expression in rat lungs. Cancer Prev Res 2010; 3: 62-72.
42. Melkamu T, Zhang X, Tan J, Zeng Y, Kassie F. Alteration of microRNA expression in vinyl carbamate-induced mouse lung tumors and modulation by the chemopreventive agent indole-3-carbinol. Carcinogenesis 2009; 31: 252-258.
43. Deng X, Cao M, Zhang J, et al. Hyaluronic acid-chitosan nanoparticles for co-delivery ofMiR-34aand doxorubicin in therapy against triple negativebreast cancer. Biomaterials 2014; 35: 4333-4344.
44. Hui C, Yujie F, Lijia Y, et al. MicroRNA-34a and microRNA-21 play roles in the chemopreventive effects of 3, 6-dihydroxyflavone on 1-methyl-1-nitrosourea-inducedbreastcarcinogenesis. Breast Cancer Res 2012; 22: R80.
45. Zhao G, Guo J, Li D, et al. MicroRNA-34a suppresses cell proliferation by targeting LMTK3 in human breast cancer MCF-7 cell line. DNA Cell Biol 2013; 0: 1-9.
46. Sun H, Meng X, Han J, et al. Anticancer activity of DHA on gastric cancer-an in vitro and in vivo study. Tumour Biol 2013; 34: 3791-3800.
47. Christoffersen NR, Shalgi R, Frankel LB, et al. P53-independent upregulation of miR-34a during oncogene-induced senescence represses MYC. Cell Death Differ 2010; 17: 236-245.
48. Tran KQ, Tin AS, Firestone GL. Artemisinin triggers a G1 cell cycle arrest of human Ishikawa endometrial cancer cells and inhibits cyclin-dependent kinase-4 promoter activity and expression by disrupting nuclear factor-κB transcriptional signaling. Anticancer Drugs 2014; 25: 270-281.
49. Thanaketpaisarn O, Waiwut P, Sakurai H, Saiki I. Artesunateenhances TRAIL-induced apoptosis in human cervical carcinoma cells through inhibition of the NF-κB and PI3K/Akt signaling pathways. Int J Oncol. 2011; 39: 279-285.
50. McGovern PE, Christofidou-Solomidou M, Wang W, Dukes F, Davidson T, El-Deiry WS. Anticancer activity of botanical compounds in ancient fermented beverages. Int J Oncol 2010; 37: 5-14.
51. Aggarwal BB, Ichikawa H. Molecular targets and anticancer potential of indole-3-carbinol and its derivatives. Cell Cycle 2005; 4: 1201-1215.
52. Howells LM, Moiseeva EP, Neal CP, et al. Predicting the physiological relevance of in vitro cancer preventative acivities of phytochemicals. Acta Pharmacol Sin 2007; 28: 1274-1304.
53. Reed GA, Peterson KS, Smith HJ, et al. A phase I study of indole-3-carbinol in women: tolerability and effects. Cancer Epidemiol. Biomarkers Prev. 2005; 14: 1953-1960.
54. Gordi T, Huong DX, Hai TN, Nieu NT, Ashton M. Artemisinin pharmacokinetics and efficacy in uncomplicated-malaria patients treated with two different dosage regimens. Antimicrob Agents Chemother. 2002; 46: 1026-1031.
55. Aronchik I, Chen T, Durkin KA, et al. Target protein interactions of indole-3-carbinol and the highly potent derivative 1-benzyl-I3C with the C-terminal domain of human elastase uncouples cell cycle arrest from apoptotic signaling. Mol Carcinogen 2012; 51: 881-894.